Cosmo Pharmaceuticals Partner Sun Pharma Receives the Health Canada’s Approval of Winlevi (clascoterone cream) for Topical Treatment of Acne
Shots:
- Cosmo Pharmaceuticals highlighted that its partner Sun Pharma has received marketing authorization from Health Canada for Winlevi (clascoterone cream 1%) to treat patients with acne vulgaris (acne)
- The 2 P-III studies showed that patients treated with Winlevi (androgen receptor inhibitor) achieved success based on IGA @12wk. (18.8% & 20.9%) vs (8.7% & 6.6% in the vehicle), mean absolute change from baseline in NILCs was -20.4 & -19.5 vs -13.0 & -10.8 while 19.3 & -20.1 vs 15.4 & -12.6 in ILCs
- Winlevi is supplied in 30g aluminum tubes while each gram of Winlevi contains 10mg of clascoterone in a white to almost white cream. Winlevi is designed to reduce sebum & decrease inflammation for male & female acne patients aged ≥12yrs.
Ref: Newswire | Image: Cosmo Pharmaceuticals
Related News:- Cassiopea's Winlevi (Clascoterone Cream) Receives the US FDA's Approval for the Treatment of Acne Vulgaris
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
